SurvodutideSUR10

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Survodutide

Weight reduction and weight management

Survodutide specifications and reference prices. Select a specification to add it to your cart.

10mg/vial x 10vials

Reference priceUS$458.82

For laboratory research only. Not for human or veterinary use.

COA 检测报告 / Reports

Compare all specifications & reference prices
SKUSpecification / packReference price (USD)
SUR1010mg/vial x 10vialsUS$458.82

Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.

RESEARCH FOCUS

Main Uses & FAQs

This page organizes directly relevant information on Survodutide regarding weight loss and weight management. First, look at the research questions and findings, then verify the population or species, study preparations, and scope of interpretation.

Main TopicsWeight Loss · Weight Management
USAGE REFERENCE

Survodutide · Usage reference (for research purposes)

The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.

🧪Reconstitution

Suggested Diluent
Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
Diluent Volume
Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
Handling Notes
Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.

💾Storage

Unreconstituted Lyophilized Powder
Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
After Reconstitution
Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
Transport
For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.

📏Dosage Reference (Research)

Purpose / SettingCommon Reference
Administration RouteSubcutaneous injection

🔁Cycle

Subcutaneous Injection, Site Rotation

View the Complete Usage Guide Library →

Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.

Research SummaryKey Findings

What research findings exist for Survodutide in weight loss and weight management?

Obesity combined with diabetes In adults with diabetes at 76 weeks, weight loss was better than placebo. Another study reported that the proportion of weight loss and reaching the weight loss threshold in Survodutide group was better than placebo.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
3 Main ReferencesSorted by First Publication Date ↓
Human Study2026REF. 01

What findings do Survodutide studies on obesity combined with diabetes show?

Research Findings

Obesity combined with diabetes in adults with diabetes lost weight at 76 weeks compared to placebo.[1] ↗

Study Design

Human Phase III randomized; SYNCHRONIZE-2

Scope & Limitations

Limited trial populations and formulations.

View the Article Title and Full Citation+

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

Wharton S, le Roux CW, Startseva E, Kloer IM, Alhussein A, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Butt JH, Ekinci EI, Jastreboff AM, Ji L, Schou M, Tinahones FJ, Kokkinos AD, Merkely B, Ogawa W, Pedersen SD, Pietiläinen KH, Quinn D, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM, SYNCHRONIZE-2 Investigators.

The New England Journal of Medicine · Volume, Issue, Year 2026
First published 2026-10-01 · PMID 42820639
DOI 10.1056/nejmoa2607219

Human Study2026REF. 02

What are the results of Phase III weight loss in non-diabetic obese adults?

Research Findings

The Survodutide study group had a higher proportion of weight loss and achievement of weight reduction thresholds than placebo.[2] ↗

Study Design

725 non-diabetic obese/overweight adults; 76-week SYNCHRONIZE-1 Phase III randomized trial.

Scope & Limitations

Experimental Formulation Combined with Lifestyle Counseling; Gastrointestinal Reactions Common, Cannot Be Simply Ranked Against Other Experimental Statistical Goals or Populations.

View the Article Title and Full Citation+

Survodutide Once Weekly for the Treatment of Adults with Obesity.

le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM, SYNCHRONIZE-1 Investigators

The New England Journal of Medicine · Volume, Issue, Year 2026
First published 2026-06-07 · PMID 42253238
DOI 10.1056/NEJMoa2600751

Human Study2024REF. 03

46 weeks Survodutide dose exploration—what does it indicate?

Research Findings

The study shows weight loss in dosage groups is better than placebo, supporting direct weight management research.[3] ↗

Study Design

386 treated overweight/obese adults without diabetes; 46-week Phase II randomized trial

Scope & Limitations

Completion rate is about 60%, with planned dosage and actual maintenance dose analysis differing; Do not mix different estimated results or provide bottled usage.

View the Article Title and Full Citation+

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM

The Lancet. Diabetes & Endocrinology · Volume and issue year 2024
First published 2024-02-05 · PMID 38330987
DOI 10.1016/S2213-8587(23)00356-X

i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

GO DEEPER

What Questions Do These Studies Address?

Compare study populations, findings and scope.

↗
QUESTIONS, ANSWERED

Survodutide · Frequently Asked Questions.

What research findings exist for Survodutide in weight loss and weight management?+

Obesity combined with diabetes In adults with diabetes at 76 weeks, weight loss was better than placebo. Another study reported that the proportion of weight loss and reaching the weight loss threshold in Survodutide group was better than placebo.[1] ↗ [2] ↗

Can weight loss results for populations with and without diabetes be directly combined for comparison?+

Not suitable. The two phase III trials of Survodutide were conducted in populations with and without diabetes, respectively. Weight results should be understood according to the enrollment criteria, follow-up, and statistical objectives of each trial, and the percentages from different trials should not be simply ranked.[1] ↗ [2] ↗

Survodutide—these conclusions apply to which study populations?+

Human Phase III randomized; SYNCHRONIZE-2; 725 non-diabetic obese/overweight adults; 76-week SYNCHRONIZE-1 Phase III randomized trial; 386 treated non-diabetic overweight/obese adults; 46-week Phase II randomized trial. Limited trial populations and formulations.[1] ↗ [2] ↗ [3] ↗

VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL

Research peptides. Shop by product.

Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.

Ventro Peptides & Biotech Logo
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT

01 / CATALOG

Browse products

7 products Product names, specifications, and prices follow the current quotation
SemaglutideSM10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Semaglutide

10mg/vial x 10vials

US$90.91
TirzepatideTR20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Tirzepatide

20mg/vial x 10vials

US$160.61
RetatrutideRT10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Retatrutide

10mg/vial x 10vials

US$109.09
BPC157BC10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Repair & Recovery Research

BPC157

10mg/vial x 10vials

US$133.33
MOTS-CMS20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Longevity & Mitochondrial Research

MOTS-C

20mg/vial x 10vials

US$257.58
LiraglutideLR10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Liraglutide

10mg*10vials

US$164.71
IGF-lr3IG1COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Growth Hormone & IGF-1

IGF-lr3

1mg/vial x 10vials

US$505.88

03 / ABOUT VENTRO

Reliable peptide supply, built for long-term partnerships.

Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.

  • High-purity peptides
  • Available COA reports
  • COA & quality documentation
  • Flexible small-quantity purchases
  • Reliable global fulfillment
  • Research product retail support

04 / QUALITY SYSTEM

Quality without compromise

Browse the available COA reports by product. Confirm documentation for your order with our team.

Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support

RESEARCH PRODUCT INQUIRY

Submit a product inquiry

Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

Contact Ventro

Choose a channel to contact the Ventro team directly.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

WhatsApp